DUBLIN--(BUSINESS WIRE)--The "Viral Vector Manufacturing - Market Analysis, Trends, and Forecasts" report has been added to ResearchAndMarkets.com's offering.
The Viral Vector Manufacturing market worldwide is projected to grow by US$860 Million, driven by a compounded growth of 20.6%.
Retroviral Vectors, one of the segments analyzed and sized in this study, displays the potential to grow at over 18.4%. The shifting dynamics supporting this growth makes it critical for businesses in this space to keep abreast of the changing pulse of the market. Poised to reach over US$364.1 Million by the year 2025, Retroviral Vectors will bring in healthy gains adding significant momentum to global growth.
Representing the developed world, the United States will maintain a 22.2% growth momentum. Within Europe, which continues to remain an important element in the world economy, Germany will add over US$32.7 Million to the region's size and clout in the next 5 to 6 years. Over US$40.9 Million worth of projected demand in the region will come from the rest of the European markets.
In Japan, Retroviral Vectors will reach a market size of US$30.7 Million by the close of the analysis period. As the world's second largest economy and the new game changer in global markets, China exhibits the potential to grow at 20.2% over the next couple of years and add approximately US$150.8 Million in terms of addressable opportunity for the picking by aspiring businesses and their astute leaders.
Presented in visually rich graphics are these and many more need-to-know quantitative data important in ensuring quality of strategy decisions, be it entry into new markets or allocation of resources within a portfolio. Several macroeconomic factors and internal market forces will shape growth and development of demand patterns in emerging countries in Asia-Pacific.
All research viewpoints presented are based on validated engagements from influencers in the market, whose opinions supersede all other research methodologies.
Competitors identified in this market include:
- Cell & Gene Therapy Catapult
- Cobra Biologics
- FujiFilm Diosynth Biotechnologies U.S.A. Inc.
- Lonza Group AG
- Merck KGaA
- Oxford Biomedica plc
- Spark Therapeutics Inc.
- uniQure N.V.
For more information about this report visit https://www.researchandmarkets.com/r/gvfhda